

Title: Patient burden with current surveillance paradigm and factors associated with interest in altered surveillance for early stage HPV-related oropharyngeal cancer

Running head: Interest in altered surveillance

Authors: Laila A. Gharzai MD LLM,^{1,2} Nicholas Burger BS,³ Pin Li PhD,⁴ Elizabeth M. Jaworski MD MS,¹ Caitlin Henderson NP,¹ Matthew Spector MD,³ Andy Rosko MD,³ Michelle M. Chen MD,³ Mark E. Prince MD,³ Carol R. Bradford MD,³ Kelly M. Malloy MD,³ Chaz L. Stucken MD,³ Paul Swiecicki MD,⁵ Francis Worden MD,⁵ Matthew J. Schipper PhD,⁴ Caitlin A. Schonewolf MD,¹ Jennifer Shah MD,¹ Reshma Jagsi MD DPhil,^{1,2} Steve Chinn MD,³ Andrew Shuman MD,³ Keith Casper MD,^{3*} Michelle L. Mierzwa MD MS^{1*}

1. Department of Radiation Oncology, University of Michigan
2. Center for Bioethics and Social Sciences in Medicine, University of Michigan
3. Department of Otolaryngology, University of Michigan
4. Department of Biostatistics, University of Michigan
5. Department of Medical Oncology, University of Michigan

* Co-last authors

Corresponding Author:

Michelle Mierzwa, MD
Department of Radiation Oncology
University of Michigan
1500 E. Medical Center Drive, Ann Arbor, MI 48109
Tel: (734) 936-4300, Fax: (734) 763-7370
E-mail: mmierzwa@med.umich.edu

Manuscript Word Count: 3182 of 4000 word limit

Abstract Word Count: 246 of 250 word limit

Funding: Michigan Institute for Clinical & Health Research grant support (CTSA: UL1TR002240)

Conflicts of Interest: The authors report no conflicts of interest.

Keywords: surveillance, oropharyngeal cancer, human papillomavirus, survivorship

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/onco.13784](https://doi.org/10.1002/onco.13784)

This article is protected by copyright. All rights reserved.

Abstract

Introduction: Optimal surveillance paradigms for survivors of early stage human papillomavirus (HPV)-related oropharyngeal cancer are not well defined. This study aimed to characterize patient interest in and factors associated with an altered surveillance paradigm.

Materials and Methods: We surveyed patients with Stage I or II HPV-related oropharyngeal cancer treated at a tertiary care institution from 2016 to 2019. Primary outcomes were descriptive assessment of patient knowledge, interest in altered surveillance, burdens of in-person appointments, and priorities for surveillance visits. Ordinal regression was used to identify correlates of interest in altered surveillance.

Results: Sixty-seven patients completed surveys from February to April 2020 at a median of 21 months since completing definitive treatment. A majority (61%) of patients were interested in a surveillance approach that decreased in-person clinic visits. Patients who self-identified as medical maximizers, had higher worry of cancer recurrence, or were in long-term relationships were less likely to be interested. Patients reported significant burdens associated with surveillance visits, including driving distance, time off work, and non-medical costs. Patients were most concerned with discussing cancer recurrence (76%), physical quality of life (70%), mortality (61%), and mental quality of life (52%) with their providers at follow-up visits.

Conclusions: Patients with early stage HPV-related oropharyngeal cancers are interested in altered surveillance approaches, experience significant burdens related to surveillance visits, and have concerns that are not well addressed with current surveillance approaches, including physical and mental quality of life. Optimized surveillance approaches should incorporate patient priorities and minimize associated burdens.

Implications for Practice

The number of patients with HPV-related oropharyngeal cancers is increasing, and numerous clinical trials are investigating novel approaches to treating these good-prognosis patients. There has been limited work assessing optimal surveillance paradigms in these patients. Patients experience significant appointment-related burdens, and have concerns such as physical and mental quality of life. Additionally, patients with early stage HPV-related oropharyngeal cancers express interest in altered surveillance approaches that decrease in-person clinic visits.

Optimization of surveillance paradigms to promote broader survivorship care in clinical practice is needed.

Introduction

Early stage human papillomavirus (HPV)-related oropharyngeal cancer represents a distinct entity among head and neck malignancies given better outcomes¹ and differing demographics² compared to HPV-negative head and neck cancers. Five-year overall survival rates are in excess of 85% in patients with HPV-related cancers,^{3,4} whereas patients with HPV-negative cancers have a 5-year overall survival of less than 50%.¹ In HPV-related cancers, Stage I-III patients with a negative positron emission tomography scans at three months post-treatment have a 5-year disease-free survival of 91% and 5-year overall survival of 89%.⁵

Much contemporary clinical research in these patients currently focuses on treatment de-intensification strategies, including alterations in systemic therapies⁶ and radiation approaches,⁷⁻⁹ aiming to reduce the known long-term toxicities of treatment (80% peripheral neuropathy,¹⁰ 40% ototoxicity,¹¹ 30% nephrotoxicity,¹² 15-20% late dysphagia,^{13, 14} 15% late xerostomia^{15, 16}) and their subsequent impact of quality of life.^{17, 18} HPV-related oropharynx cancer specific surveillance after standard therapy, however, has not been well-studied. Current surveillance paradigms offer the same surveillance schedule for all squamous cell carcinomas of the head and neck regardless of HPV status,¹⁹ ignoring vastly different outcomes, recurrence patterns, demographics, and comorbidities.²⁰ Recognizing the lower rates of recurrences in HPV-related cancers as above, revising current surveillance guidelines to de-intensify surveillance in good-prognosis patients warrants further evaluation.

Observational epidemiology studies in HPV-related oropharynx cancer patients suggest that recurrences are frequently detected in the setting of new symptoms, rather than during surveillance visits. Moreover, adherence to standard surveillance paradigms offers limited

tangible benefits.²¹ Additionally, current surveillance options do not offer a means to detect distant recurrences, which is proportionally more common in this patient population.²²

As we seek ways to improve surveillance options for HPV-related oropharyngeal cancer, patient input is critical. Patient burdens related to appointments and patient desires to address specific concerns during surveillance may illuminate methods to optimize broader survivorship care in addition to standard cancer recurrence surveillance. We aimed to assess patient interest in and factors associated with alternative surveillance approaches, including patient knowledge, burdens of in-person appointments, and priorities for follow-up visits.

Methods

Study Population and Data Collection

Patients who completed treatment for American Joint Commission on Cancer (AJCC) 8 Stage I or II HPV-related (assessed by p16 positivity²³) oropharyngeal cancers without evidence of cancer recurrence and who had been seen at the University of Michigan within the past six months were eligible. All patients were followed with standard surveillance recommendations, which include clinic visits and nasopharyngolaryngoscopy every three months for the first two years after treatment, and every four to six months years 3-5. The survey instrument was approved by University of Michigan's Institutional Review Board as part of a larger study following head and neck cancer patients (HUM00042189). Patients were enrolled and consented either while in clinic for a scheduled surveillance visit or via phone, and completed the survey electronically. Study data were collected and managed using research electronic data capture (REDCap) tools.^{24, 25}

Measures

Study participants completed a 38-item survey (see Supplement). The instrument was based on Andersen's Health Service Utilization Model,²⁶ developed using standardized approaches to questionnaire design,²⁷ and based on systematic review of the literature, prior research in head and neck cancer patients, input from a multidisciplinary team, and survey design experts.

Information on patient sex, age, education, race/ethnicity, employment, and income was obtained from the survey. Details on cancer staging and treatment received were obtained from the medical record.

Questions regarding HPV etiology,²⁸ cancer worry,²⁹ self-assessment of health status,³⁰ trust in healthcare providers,³¹ shared decision-making preferences,³² health literacy³³ and medical maximizer/minimizer preferences^{34,35} were adapted from previous reports in the literature.

Medical minimizer/maximizer preferences distinguish patients who tend to prefer aggressive versus more passive approaches to healthcare.³⁶ Concerns related to treatment were adapted from the literature³⁷ and consisted of 11 topics rated on a 3-point scale (not at all, somewhat, and very much); these were used as proxies of items to be addressed during surveillance visits.

Surveillance-related burdens were assessed through self-report of time allotted for surveillance visits, method for taking time off work, method of and difficulty of travel to appointments, and money spent on co-pays and other associated costs (including food, gas, lodging).

The survey presented scenarios to address options for altered surveillance patterns that included decreased clinic visits and assessed interest in non-clinic methods of surveillance. In Scenario 1, patients were offered a vignette and asked to rate interest in returning to clinic for fewer routine surveillance visits, from every three months in the first two years after treatment to every six to twelve months; in Scenario 2, patients were then offered a similar vignette with additional education on the expected low risk of recurrence, and again asked to rate interest in altered

surveillance. For exploratory analyses, responses for Scenario 2 were utilized as this scenario represents discussions that occur in routine clinical practice. Patients were also asked about potential adjuncts to standard surveillance including blood samples, urine samples, electronic symptom surveys, or expedited symptom-directed survivorship visits (for example, speech language pathology).

Statistical Analysis

The primary aim of this analysis was to descriptively assess interest in altered surveillance, patient burdens of appointments, and patient priorities for follow-up. Interest in altered surveillance was defined as responses of 4 or 5 on a Likert-type scale from 0 to 5, where 0 represented “not at all interested” and 5 represented “definitely interested.” Wilcoxon signed-rank test was used to compare means between the two scenarios. Treatment-related concerns were analyzed as binary, with “not at all” compared to “somewhat” and “very much”.

Exploratory analyses included associating five pre-specified variables to avoid overfitting the data (relationship status, worry of cancer recurrence, self-perception of physical health, shared decision-making preferences, minimizer-maximizer preferences) with interest in altered surveillance using ordinal regression. Chi-squared test was used to assess changes in concern with median follow-up time. The data were analyzed using the Statistical Package for Social Sciences, version 26 (SPSS, Chicago, IL). Two-sided p-values ≤ 0.05 were considered statistically significant.

Results

Sample

Of 90 patients invited to participate, 67 completed surveys for a 74.4% response rate. Patients received treatment from October 2016 to December 2019, and surveys were completed February to April 2020 at a median of 21.2 months since completing treatment (range, 2.8 to 41 months). Patients had 71.6% AJCC 8 Stage I disease, and 73.1% underwent definitive chemoradiation for treatment. Patients had a median age of 60 years (range, 41-83), 92.5% were male, 97% of patients were non-Hispanic white, 53.7% had a bachelor's degree or higher, and 86.6% were in a long-term relationship. Most patients were working at time of survey (61.1%) and nearly half made \geq \$100,000 per year (Table 1).

Patients exhibited high levels of self-assessment of physical health, with 64.2% assessing health as excellent or very good. Most patients exhibited preferences for a spectrum of shared decision making, with only 3% preferring to leave decision-making up to the physician and no patients wanting to make the decision themselves. All exhibited trust in their healthcare provider (100% yes or definitely yes to some extent). Most patients self-identified as medical maximizers (71.6%), most had low levels of cancer worry (mean 5.48, standard deviation 3.56 on 20-point scale), and most reported high levels of health literacy (86.6%, Table 2).

Knowledge

Almost all patients knew that HPV caused their cancer (94.0%), and most agreed that their particular cancer was unlikely to recur (74.6%). Most patients characterized risk of recurrence in either a local or distant location as low or very low (70.1%). Slightly more patients expected a recurrence to be local, although the proportion was near 50% in both: 58% of patients agreed with the statement “if my cancer comes back, it is likely to come back in my throat”; 53% of patients agreed with the statement “if my cancer comes back, it is likely to come back elsewhere in my body.”

Altered Surveillance

Patients were asked to report interest in decreasing in-person post-treatment surveillance clinic visits. In Scenario 1 asking about patient interest in decreased in-clinic surveillance visits, 55.2% of patients were interested in altered surveillance (rated 4-5 on Likert scale) and only 8.9% were not interested at all (rated 0-1 on Likert scale). When offered additional information regarding low risk of recurrence before asking again about interest in decreased in-clinic surveillance visits in Scenario 2, 61.2% were interested in altered surveillance (rated 4-5 on Likert scale) and only 7.4% were not interested at all (rated 0-1 on Likert scale). Comparison of responses to both scenarios showed there was no significant difference in responses to Scenario 1 (mean 3.46, standard deviation 1.50) versus Scenario 2 (mean 3.58, standard deviation 1.36, $p=0.203$).

An exploratory analysis of factors associated with interest in altered surveillance were assessed with an ordinal regression model incorporating pre-specified variables of relationship status, worry of cancer recurrence, self-perception of physical health, shared decision-making preferences, and minimizer-maximizer preferences. On multivariable regression, being a medical maximizer (higher on the minimizer-maximizer scale, OR 0.64, 95% CI 0.45-0.89, $p=0.008$), being in a long-term relationship (OR 0.12, 95% CI 0.03-0.56, $p=0.007$), and having higher worry of cancer recurrence (OR 0.86, 95% CI 0.75-0.99, $p=0.041$) were all associated with decreased interest in altered surveillance, whereas physical health ($p=0.36$) and shared decision-making ($p=0.60$) were not associated with interest in altered surveillance. Although time from end of treatment was not pre-specified as a variable of interest, in a separate model, time from the end of treatment was assessed and was not significantly associated with interest in altered surveillance.

Patients were asked to select from four non-clinic based surveillance options as a means to supplement surveillance. When asked to select only one option, 61% selected blood samples as the preferred non-clinic way to follow cancer, 19% selected surveys, 10% selected symptom-directed survivorship visits, and 9% selected urine samples. When allowed to select multiple options as a non-clinic based surveillance option, 94% selected blood samples, 63% selected urine samples, 58% selected surveys, and 48% selected symptom-management visits.

Surveillance Burden

Patients were asked to assess varying burdens related to surveillance appointments. Most patients felt it was easy to get to follow-up appointments, with 59.7% stating “very easy” and 32.8% stating “somewhat easy”. A minority of patients (9.0%) felt that it was somewhat difficult to come to appointments. Patients drove a median of 57 miles to reach appointments (range, 2-346 miles) and 22.4% of patients drove more than 100 miles to come to appointments.

Patients allotted a significant portion of their day to be able to attend surveillance visits. Over 80% of patients allotted a half day or more to attend a single surveillance visit, with nearly half of patients allotting at least a half day (49.3%), and 26.9% allotting a full working day for one appointment. A minority of patients, 6.0%, allotted more than one full day (this presumably includes an overnight stay for those who drove from long distances). To obtain time off from work in order to attend these visits, 19.4% used unpaid time off, and 16.4% used sick days, vacation days, or the Family-Medical Leave Act to take time off; 41.8% of patients did not work.

Almost all patients, 98.5%, had health insurance. Patients were asked to estimate direct cost to them associated with surveillance visits. Patients were first asked about co-pays, or immediate out of pocket costs associated with the visit itself. Nearly half of patients (46.3%) were unable to

identify an amount. In free text, 21 patients stated that they did not know the amount; two patients stated that it varies; one person gave a percent based on insurance; two patients stated “up to” a certain dollar amount (\$1000 and \$3500 for these two patients, presumably reflecting insurance deductible amounts). Two patients explicitly stated that they had a very high deductible plan; 19.4% of patients did not pay any co-pay. The remaining 34.3% reported a range of costs, with 17.9% reporting \$26-50 and 7.5% reporting >\$50.

Patients were also asked to estimate out of pocket costs related to gas, food, or lodging for each visit; 17.9% of patients were unsure or reported no costs. The remaining 82.1% reported some cost, with 40.3% reporting \$1-25 in cost, 19.4% reporting \$26-50, and 22.4% reporting >\$50 (Table 3). For all patients who reported a dollar amount for co-pay or non-medical out of pocket cost, 22.4% of patients reported spending more than \$100. Of note, the costs assessed here did not include medical bills or additional subsequent costs from the healthcare system or insurers.

Priorities for surveillance

Treatment-related concerns were elicited from each patient to allow for outlining concerns that could be addressed during surveillance care. Cancer recurrence remained the most important concern, with 76% of patients noting this as somewhat or very important. Mortality was important to 61% of patients. Physical quality of life was important to 70% of patients, and mental quality of life was important to 52% of patients. The rest of the 11 concerns were noted as important by less than half of patients (see Figure 1); notably, despite the costs noted above, 79% of patients reported that financial issues were not a concern.

Discussion

Patients with early-stage HPV-related oropharyngeal cancer offer insights into ways to optimize surveillance and survivorship care. As the treatment paradigm for HPV-related cancers continues to evolve, efforts must also focus on individualizing follow-up care based upon the outcomes of the disease itself and patient preferences.

Substantial work in careful treatment de-intensification in these excellent-prognosis patients is ongoing. While RTOG 1016⁶ and De-ESCALaTE³⁸ have shown that de-escalating systemic therapy with cetuximab failed, other approaches are investigating numerous promising approaches to de-escalation such as the use of induction chemotherapy,³⁹ decreasing radiation dose⁴⁰ or volumes,⁴¹ or modifying indications for post-operative treatment. As these investigations cautiously continue, standard of care therapy should remain unchanged as standard of care is associated with excellent outcomes. In contrast to treatment studies, current surveillance paradigms do not differentiate follow-up recommendations by HPV status, and do not adapt to the excellent outcomes in HPV-related populations. The current study aimed to obtain the patient perspective on altered surveillance to inform strategies to optimize surveillance in the HPV-related population.

A substantial portion of patients (61.2%) would be interested in a post-treatment surveillance option that included fewer clinic visits. There was no significant increase in interest with additional information provided in the vignette for Scenario 2, possibly reflecting the high knowledge of this population regarding HPV-related cancer outcomes and etiology. Cancer-related knowledge was higher in this study as compared to previous reports, which have previously suggested that the proportion of patients with HPV-related oropharyngeal cancer understanding the viral etiology of their cancer may be as low as 35%.^{28, 42} The exploratory analysis of factors that correlated with interest in altered surveillance is in line with what many

physicians intuitively know to be true: some patients are intrinsically more likely to seek out healthcare (medical maximizers) or are more worried about cancer recurrence.⁴³ Here, we see that these intuitive perceptions about patients may play out as interest in novel surveillance or treatment paradigms.

It is possible that the proportion of patients who are interested in remote approaches or decreased surveillance may have increased due to the ongoing COVID-19 pandemic and current interest in fewer surveillance visits may be higher under current circumstances. Additionally, telemedicine capabilities have increased as a result of COVID-19 in tandem with favorable reimbursement modifications, likely making remote monitoring more accessible at head and neck cancer centers.⁴⁴ A recent telephone-based quality of life survey in oral cavity cancer patients showed that remote monitoring via patient-reported outcomes may offer an excellent means to detect cancer recurrences while managing appointment-related burdens.⁴⁵

In this study, patients reported significant burdens associated with surveillance visits at a tertiary care facility, including a substantial distance driven for each appointment, allotting a significant portion of a working day for a single visit, and costs including co-pays and other non-medical costs associated with each visit. Interestingly, a substantial portion of patients in this sample reported uncertainty with identifying their typical co-pay costs (46.3%) and other non-medical out-of-pocket costs (10.4%), with the former possibly reflecting poor transparency in medical billing and suggesting that these financial burdens may be higher than reported in this study. Despite this, 22.4% of patients reported spending >\$100 per visit on these costs.

Importantly, almost all patients in this study were insured, and the costs reported here likely underestimate these burdens in the wider population. Additionally, these costs did not include direct medical bills related to surveillance. We have previously shown that 33% of head and neck

cancer patients going through radiation treatment reported at least a moderate financial burden from treatment, and this was associated with increased treatment non-compliance.⁴⁶ While 79% of participants in this study reported that financial issues were not a concern, possibly reflecting the relatively affluent population studied here, options that incorporate fewer in-person surveillance visits and more remote monitoring may help offset these patient-borne burdens without compromising ability to detect recurrences.

Patients reported concerns that they wished to address during surveillance visits. Consistent with prior reports,³⁷ patients rated cancer recurrence as the most important concern (76%); the next most important concern was physical quality of life (70%). Current surveillance approaches focus on the risk of local recurrence, with frequent nasopharyngoscopy to directly assess for recurrence. Despite clinical practice guidelines that have endorsed comprehensive survivorship care,^{47, 48} it remains challenging to implement surveillance approaches that cover all of these comprehensive facets and new approaches are needed. For example, incorporation of quality of life and patient reported outcomes into optimized surveillance approaches may offer a means to meet goals outlined for survivorship care.

Due to recent publications investigating the use of circulating tumor DNA in surveillance of patients with HPV-related cancers,⁴⁹ this topic was included in the survey. Patients were most interested in including blood tests as a non-clinic based surveillance options to incorporate into care. This may be reflective of standard association of blood tests with clinical care; it may also be reflective of publicity surrounding the use of circulating tumor DNA to follow patients with HPV-related cancers.⁴⁹ Further studies validating the role of circulating tumor DNA into surveillance are needed. When allowed to select multiple options for adjuncts to surveillance, over half of patients selected urine tests or surveys, offering two additional tools to add to

surveillance that could potentially be administered remotely and subsequently minimize surveillance-related burdens. Additionally, patient-reported quality of life metrics may offer a means to tailor survivorship symptom directed visits and better incorporate patient preferences. They may also allow for detection of recurrence, with changes in quality of life score potentially predicting for both local and distant recurrence.^{45, 50} Systematic administration of quality of life instruments in the metastatic setting has been shown to improve quality of life⁵¹ and increase overall survival.⁵² Patients in this study were least interested in symptom-directed visits such as speech-language pathology visits for dysphagia, suggesting that engaging patients in identifying optimal methods to incorporate survivorship care is needed.

Current surveillance recommendations do little to address long-term quality of life or survivorship issues in head and neck cancer patients. Survivorship care after cancer treatment has several components: the detection of recurrences and new cancers, which is well-addressed by current surveillance recommendations, but also physical effects of treatment, psychosocial effects of treatment, health promotion, and management of chronic conditions,⁵³ the latter four of which are poorly addressed by current surveillance paradigms despite publication of survivorship guidelines.^{47, 48} With patient interest in decreased clinic visits as demonstrated in the current survey study and need to address these additional domains of survivorship care, there is opportunity to improve surveillance paradigms especially in this good prognosis group of HPV-related oropharynx cancer patients.

Strengths of this study include its high survey response rate, indicating that these responses likely represent the wider early-stage HPV population seen at this tertiary academic center. The older white male population is reflective of the population predicted to hold the largest burden of HPV-related cancers in the United States in the coming decades.⁵⁴ Limitations of this study


include its small sample size, single institution, and lack of diversity. Minorities have worse outcomes in this cancer subtype⁵⁵ and it may be expected that the characteristics and perspectives described in this study may differ for a more diverse population, such as one that is more diverse in race, income, and insurance status. Additionally, all patients surveyed here were patients at a tertiary care institution, and it is unclear how priorities and burdens may change for patients treated in smaller community centers. Finally, this study did not include items specific to telemedicine or radiologic surveillance for distant disease. Current head and neck cancer guidelines do not incorporate routine imaging, but recent publications suggest this may be of interest in developing future altered surveillance methods.^{56, 57}

Conclusion

In conclusion, patients with early stage HPV-related oropharyngeal cancers are interested in altered survivorship paradigms, experience significant time and cost burdens related to surveillance visits, and have concerns that are not well addressed in the current paradigm including physical and mental quality of life. Optimized surveillance approaches should incorporate these patient priorities and minimize associated burdens.

Figure

Figure 1: Treatment-related concerns listed as important by patients.



Tables

Table 1: Sample characteristics

	n	%
<i>Patient Characteristics</i>		
Age (years)		
Median	60	
Min	41	
Max	83	
Gender		
Male	62	92.5%
Female	5	7.5%
Smoking Status (at time of treatment)		
Never Smoker	40	59.7%
Former Smoker	23	34.3%
Current Smoker	4	6.0%
Race/Ethnicity		
Non-Hispanic White	65	97.0%
Black	1	1.5%
Prefer not to answer	1	1.5%
<i>Tumor and Treatment Characteristics</i>		
AJCC 8 Group Stage		
I	48	71.6%
II	19	28.4%
Primary Therapy		
Chemoradiation	49	73.1%
Radiation	5	7.5%
Surgery	13	19.4%
Median time since end of treatment (months)	21.2	
Min	2.8	
Max	41.0	
<i>Socioeconomic characteristics</i>		
Education		
High school or less	8	11.9%
Some college or trade school	23	34.3%
Bachelor's degree or higher		53.7%
In long-term relationship		
Yes	58	86.6%
No	9	13.4%
Employment status		

Working full-time	34	50.7%
Working part-time	7	10.4%
Not working	26	38.8%
Health insurance		
Yes	66	98.5%
No	1	1.5%
Financial dependents		
0-1	46	68.7%
2+	21	31.3%
Household income		
Less than \$50,000	9	13.4%
\$50,000 to \$99,999	16	23.9%
\$100,000 or more	30	44.8%
I prefer not to answer	12	17.9%

Table 2: Health-related preferences

	n	%
Self-assessment of physical health		
Excellent	14	20.9%
Very Good	29	43.3%
Good	18	26.9%
Fair	5	7.5%
Trust in healthcare provider		
Yes, definitely	66	98.5%
Yes, to some extent	1	1.5%
No, not at all	0	0.0%
Shared decision making preferences		
I prefer to make the final treatment decision	0	0.0%
I prefer to make the final treatment decision after seriously considering my doctor's opinion	24	35.8%
I prefer that my doctor and I share responsibility for deciding which treatment is best.	33	49.3%
I prefer that my doctor makes the final treatment decision, but seriously considers my opinion.	8	11.9%
I prefer to leave all treatment decisions to my doctor.	2	3.0%
Medical Minimizer-Maximizer Scale		
Maximizer	48	71.6%
Minimizer	19	28.4%
Health Literacy: confidence in filling out forms		
All of the time	58	86.6%
Most of the time	6	9.0%
Some of the time	1	1.5%
A little of the time	2	3.0%
None of the time	0	0.0%
Worry of Cancer Recurrence		
Mean	5.48	

Standard Deviation	3.56	
--------------------	------	--

Table 3: Costs associated with surveillance visits. Copay costs indicate money due by the patient at the time of appointment. Out-of-pocket costs reflect gas, food, lodging, or other non-medical costs. Total costs are the sum of these two for all patients that reported at least one of these costs; not available in this latter column indicates participants who did not mark any costs down for either prior column. Of note, costs assessed here did not include medical bills or additional subsequent costs from the healthcare system or insurers.

Dollar Amount	Co-pay		Out-of-pocket costs		Total costs	
	n	%	n	%	n	%
\$101+	3	4.5%	6	9.0%	15	22.4%
\$51-100	2	3.0%	9	13.4%	7	10.4%
\$26-50	12	17.9%	13	19.4%	13	19.4%
\$1-25	6	9.0%	27	40.3%	27	40.3%
\$0	13	19.4%	5	7.5%	5	7.5%
N/A	31	46.3%	7	10.4%	7	10.4%

References

1. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. *N Engl J Med*. Jul 1 2010;363(1):24-35. doi:10.1056/NEJMoa0912217
2. Dahlstrom KR, Bell D, Hanby D, et al. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. *Oral Oncol*. Sep 2015;51(9):832-8. doi:10.1016/j.oraloncology.2015.06.005
3. van Gysen K, Stevens M, Guo L, et al. Validation of the 8(th) edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. *BMC Cancer*. Jul 9 2019;19(1):674. doi:10.1186/s12885-019-5894-8
4. Malm IJ, Fan CJ, Yin LX, et al. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. *Cancer*. May 15 2017;123(10):1768-1777. doi:10.1002/cncr.30512
5. Ng SP, Johnson JM, Gunn GB, et al. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. *Int J Radiat Oncol Biol Phys*. Nov 15 2018;102(4):1029-1035. doi:10.1016/j.ijrobp.2018.06.031
6. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. *Lancet*. Jan 5 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X
7. Yom SS, Torres-Saavedra P, Caudell JJ, et al. NRG-HN002: A Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer. *International Journal of Radiation Oncology*Biophysics*Physics*. 2019;105(3):684-685.
8. Chera BS, Amdur RJ, Green R, et al. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. *J Clin Oncol*. Aug 2019;JCO1901007. doi:10.1200/JCO.19.01007
9. Swisher-McClure S, Lukens JN, Aggarwal C, et al. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx. *International Journal of Radiation Oncology, Biology, Physics*. 03/15/2020 2020;106(4)doi:10.1016/j.ijrobp.2019.11.021
10. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? *Anticancer Drugs*. Jun 1995;6(3):369-83. doi:10.1097/00001813-199506000-00003
11. Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. *J Clin Oncol*. Aug 20 2007;25(24):3759-65. doi:10.1200/JCO.2006.08.9540
12. Doby DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. *J Pharmacol Exp Ther*. Jun 1980;213(3):551-6.
13. Dong Y, Ridge JA, Li T, et al. Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer. *Oral Oncol*. Aug 2017;71:122-128. doi:10.1016/j.oraloncology.2017.05.009
14. Gharzai LA, Li P, Schipper MJ, et al. Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma. *Oral Oncol*. Aug 14 2020;111:104853. doi:10.1016/j.oraloncology.2020.104853

15. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). *Int J Radiat Oncol Biol Phys*. Apr 2010;76(5):1333-8. doi:10.1016/j.ijrobp.2009.04.011
16. Chen AM, Daly ME, Farwell DG, et al. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. *JAMA Otolaryngol Head Neck Surg*. Feb 2014;140(2):129-33. doi:10.1001/jamaoto.2013.5988
17. Hawkins PG, Kadam AS, Jackson WC, Eisbruch A. Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. *Semin Radiat Oncol*. Jan 2018;28(1):46-52. doi:10.1016/j.semradonc.2017.08.002
18. Nayak SG, Pai MS, George LS. Quality of life of patients with head and neck cancer: A mixed method study. *J Cancer Res Ther*. Jul-Sep 2019;15(3):638-644. doi:10.4103/jcrt.JCRT_1123_16
19. National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2020). Accessed August 01, 2020, https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
20. Guo T, Rettig E, Fakhry C. Understanding the Impact of Survival and Human Papillomavirus Tumor Status on Timing of Recurrence in Oropharyngeal Squamous Cell Carcinoma. *Oral Oncology*. 2016 Jan 2016;52doi:10.1016/j.oraloncology.2015.10.016
21. Masroor F, Corpman D, Carpenter DM, Ritterman Weintraub M, Cheung KHN, Wang KH. Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma. *JAMA Otolaryngology Head & Neck Surgery*. 08/08/2019 2019;145(10)doi:10.1001/jamaoto.2019.1934
22. Imbimbo M, Alfieri S, Botta L, et al. Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. *Otolaryngol Head Neck Surg*. Oct 2019;161(4):635-642. doi:10.1177/0194599819860808
23. El-Naggar AK, Westra WH. p16 Expression as a Surrogate Marker for HPV-related Oropharyngeal Carcinoma: A Guide for Interpretative Relevance and Consistency. *Head & Neck*. 2012 Apr 2012;34(4)doi:10.1002/hed.21974
24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. Apr 2009;42(2):377-81. doi:10.1016/j.jbi.2008.08.010
25. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. Jul 2019;95:103208. doi:10.1016/j.jbi.2019.103208
26. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? *J Health Soc Behav*. Mar 1995;36(1):1-10.
27. Fowler FJ. *Survey Research Methods (Applied Social Research Methods)*. Fifth ed. SAGE Publications; 2013.
28. Milbury K, Rosenthal DI, El-Naggar A, Badr H. An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. *Oral Oncol*. Nov 2013;49(11):1067-71. doi:10.1016/j.oraloncology.2013.07.010

29. Hodges LJ, Humphris GM. Fear of recurrence and psychological distress in head and neck cancer patients and their carers. *Psychooncology*. Aug 2009;18(8):841-8. doi:10.1002/pon.1346
30. Hays RD, Spritzer KL, Thompson WW, Cella D. U.S. General Population Estimate for "Excellent" to "Poor" Self-Rated Health Item. *J Gen Intern Med*. Oct 2015;30(10):1511-6. doi:10.1007/s11606-015-3290-x
31. Campbell J, Smith P, Nissen S, Bower P, Elliott M, Roland M. The GP Patient Survey for use in primary care in the National Health Service in the UK – development and psychometric characteristics. *BMC Fam Pract*. 2009:57.
32. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. *Can J Nurs Res*. Fall 1997;29(3):21-43.
33. Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. *J Gen Intern Med*. May 2008;23(5):561-6. doi:10.1007/s11606-008-0520-5
34. Scherer LD, Zikmund-Fisher BJ. Eliciting Medical Maximizing-Minimizing Preferences with a Single Question: Development and Validation of the MM1. *Med Decis Making*. 05 2020;40(4):545-550. doi:10.1177/0272989X20927700
35. Scherer LD, Shaffer VA, Caverly T, DeWitt J, Zikmund-Fisher BJ. Medical Maximizing-Minimizing Predicts Patient Preferences for High- and Low-Benefit Care. *Med Decis Making*. Jan 2020;40(1):72-80. doi:10.1177/0272989X19891181
36. Scherer LD, Caverly TJ, Burke J, et al. Development of the Medical Maximizer-Minimizer Scale. *Health Psychol*. Nov 2016;35(11):1276-1287. doi:10.1037/hea0000417
37. Windon MJ, D'Souza G, Faraji F, et al. Priorities, concerns, and regret among patients with head and neck cancer. *Cancer*. Apr 15 2019;125(8):1281-1289. doi:10.1002/cncr.31920
38. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy Plus Cisplatin or Cetuximab in Low-Risk Human Papillomavirus-Positive Oropharyngeal Cancer (De-ESCALaTE HPV): An Open-Label Randomised Controlled Phase 3 Trial. *Lancet (London, England)*. 01/05/2019 2019;393(10166)doi:10.1016/S0140-6736(18)32752-1
39. Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. *J Clin Oncol*. Feb 10 2017;35(5):490-497. doi:10.1200/JCO.2016.68.3300
40. Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). *J Clin Oncol*. Jan 28 2021;JCO2003128. doi:10.1200/JCO.20.03128
41. Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. *Ann Oncol*. Oct 1 2019;30(10):1673. doi:10.1093/annonc/mdz171
42. Best AL, Logan RG, Vazquez-Otero C, et al. Application of a Health Literacy Framework to Explore Patients' Knowledge of the Link between HPV and Cancer. *J Health Commun*. 2018;23(8):695-702. doi:10.1080/10810730.2018.1508257
43. Llewellyn CD, Weinman J, McGurk M, Humphris G. Can we predict which head and neck cancer survivors develop fears of recurrence? *J Psychosom Res*. Dec 2008;65(6):525-32. doi:10.1016/j.jpsychores.2008.03.014

44. Centers for Medicare & Medicaid Services. Medicare Telemedicine Health Care Provider Fact Sheet. Accessed May 31, 2020, <https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet>
45. Malik A, Nair S, Sonawane K, et al. Outcomes of a Telephone-Based Questionnaire for Follow-up of Patients Who Have Completed Curative-Intent Treatment for Oral Cancers. *JAMA Otolaryngol Head Neck Surg.* Sep 2020;doi:10.1001/jamaoto.2020.2404
46. Beeler WH, Bellile EL, Casper KA, et al. Patient-reported Financial Toxicity and Adverse Medical Consequences in Head and Neck Cancer. *Oral oncology.* 2020 Feb 2020;101doi:10.1016/j.oraloncology.2019.104521
47. Cohen EE, LaMonte SJ, Erb NL, et al. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. *CA Cancer J Clin.* May 2016;66(3):203-39. doi:10.3322/caac.21343
48. Nekhlyudov L, Lacchetti C, Davis NB, et al. Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. *J Clin Oncol.* May 10 2017;35(14):1606-1621. doi:10.1200/JCO.2016.71.8478
49. Chera BS, Kumar S, Shen C, et al. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. *J Clin Oncol.* Apr 1 2020;38(10):1050-1058. doi:10.1200/jco.19.02444
50. Gharzai LA, Li P, Jaworski E, et al. Can patient reported quality of life predict locoregional recurrence in oropharyngeal cancer? - International Journal of Radiation Oncology • Biology • Physics. *IJROBP.* 2020;106(5):1199-1200. doi:doi:10.1016/j.ijrobp.2019.11.050
51. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. *J Clin Oncol.* Feb 20 2016;34(6):557-65. doi:10.1200/jco.2015.63.0830
52. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *JAMA.* 2017:197-198. vol. 2.
53. Nekhlyudov L, Mollica MA, Jacobsen PB, Mayer DK, Shulman LN, Geiger AM. Developing a Quality of Cancer Survivorship Care Framework: Implications for Clinical Care, Research, and Policy. *J Natl Cancer Inst.* 11 2019;111(11):1120-1130. doi:10.1093/jnci/djz089
54. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. *J Clin Oncol.* 06 2019;37(18):1538-1546. doi:10.1200/JCO.19.00370
55. Pike LRG, Royce TJ, Mahal AR, et al. Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. *J Natl Compr Canc Netw.* Feb 2020;18(2):177-184. doi:10.6004/jnccn.2019.7356
56. Su W, Miles BA, Posner M, et al. Surveillance Imaging in HPV-related Oropharyngeal Cancer. *Anticancer Res.* 03 2018;38(3):1525-1529. doi:10.21873/anticanres.12380
57. Canavan JF, Harr BA, Bodmann JW, et al. Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer. *Oral Oncol.* 04 2020;103:104585. doi:10.1016/j.oraloncology.2020.104585



MICHIGAN MEDICINE
UNIVERSITY OF MICHIGAN

**DEPARTMENTS OF RADIATION ONCOLOGY AND
OTOLARYNGOLOGY**

Survey on Surveillance for Head and Neck Cancer

Background

- You are invited to participate in a survey to help us understand your feelings toward the surveillance, or follow-up, of your cancer after treatment.
- This information will help us determine the best way to follow patients after completion of treatment for head and neck cancer
- This survey is for patients with HPV-related head and neck cancer, which is also sometimes called viral-associated or p16 positive cancer

Survey Information

- This survey should take approximately 15 minutes to complete
 - Your participation is completely voluntary
 - By completing and returning this survey, you are giving your consent to participate in this survey study
-

Please fill out today's date: _____

First, we're going to ask you some questions about your cancer type and your concerns related to cancer. Please check the boxes to answer each question.

1. When did you finish treatment for cancer?

- Less than 2 months ago
- 2 to 5 months ago
- 6 months ago or more

2. Rate your agreement with the following statement: The HPV virus caused my cancer.

- Disagree
- Agree

3. Rate your agreement with the following statement: Most people with cancer like me will not have their cancer come back.

- Disagree
- Agree

4. After receiving all of the planned treatments, do you consider the chance of your cancer coming back IN THE HEAD AND NECK AREA to be (*please select one*):

- Very low
- Low
- Moderate
- High
- Very high

5. After receiving all of the planned treatments, do you consider the chance of your cancer spreading TO OTHER PARTS OF YOUR BODY to be:

- Very low
- Low
- Moderate
- High
- Very high

13. There are some things that can be done to monitor cancer remotely even if they are not being seen by their providers. Which of these would make you feel most comfortable about coming in to see your provider in six to twelve months instead of every three months?

Please pick the option you are MOST INTERESTED IN DOING.

- Blood samples
- Urine samples
- Surveys about your symptoms and how you're feeling by email or online (that will be reviewed by your healthcare provider)
- Expedited appointment with a specialist for side effects of treatment (e.g. swallow specialist)

14. There are some things that can be done to monitor cancer remotely even if they are not being seen by their providers. Which of these would make you feel most comfortable about coming in to see your provider in six to twelve months instead of every three months?

Please pick ANY of the options you would be WILLING TO DO. You can check as many as you could like.

- Blood samples
- Urine samples
- Surveys about your symptoms and how you're feeling by email or online (that will be reviewed by your healthcare provider)
- Expedited appointment with a specialist for side effects of treatment (e.g. swallow specialist)

15. In general, how would you rate your physical health?

- Excellent
- Very Good
- Good
- Fair
- Poor

16. During your last appointment, did you have confidence and trust in the healthcare provider you saw or spoke to?

- Yes, definitely
- Yes, to some extent
- No, not at all
- Don't know / can't say

17. The role you play in the treatment option you choose is important. The next question will tell us how you could like the treatment decision to be made.

Please choose one of the following statements that best describes how you could like the decision to be made.

- I prefer to make the final treatment decision
- I prefer to make the final treatment decision after seriously considering my doctor's opinion
- I prefer that my doctor and I share responsibility for deciding which treatment is best.
- I prefer that my doctor makes the final treatment decision, but seriously considers my opinion.
- I prefer to leave all treatment decisions to my doctor.

18. Next, we'd like to understand what you prefer to do in situations where the treatment choice is less clear.

Sometimes, medical action is clearly necessary, and sometimes it is clearly NOT necessary. Other times, reasonable people differ in their beliefs about whether medical action is needed. In situations where it's not clear, do you tend to learn towards taking action or do you lean towards waiting and seeing if action is needed? Importantly, there is no "right" way to be.

1	2	3	4	5	6
I lean toward waiting and seeing					I lean toward taking action

Next, we're going to ask you some questions about yourself. Please check the boxes to answer each question.

1. Did your treatment for cancer include surgery?

Yes

No

2. Did your treatment for cancer include radiation?

Yes

No

3. Did your treatment from cancer include chemotherapy?

Yes

No

4. Age: _____

5. Gender:

Male

Female

Other

6. Race/Ethnicity:

Non-Hispanic White / Caucasian

Black or African American

Native American or American Indian

Asian / Pacific Islander

Hispanic

Other _____

I prefer not to answer

7. Education: What is the highest degree or level of school you have completed?
- Less than a high school diploma
 - High school degree or equivalent (e.g. GED)
 - Some college, no degree
 - Trade school or Associate degree (e.g. AA, AS)
 - Bachelor's degree (e.g. BA, BS)
 - Master's degree (e.g. MA, MS, MEd)
 - Professional degree (e.g. MD, DDS, DVM)
 - Doctorate (e.g. PhD, EdD)
 - I prefer not to answer
8. Are you in a long-term relationship?
- Yes
 - No
9. Employment status: Are you currently...?
- Working full time
 - Working part time
 - Not working
 - I prefer not to answer
10. If you take time off of work to come to your appointments, how do you get time off?
- FMLA
 - Vacation days
 - Sick days
 - Unpaid time off
 - Other _____
 - Not applicable—do not take time off work
11. How much time do you allot to come to each follow up visit?
- Less than half a day
 - Half day
 - Full day
 - More than a full day
12. Do you have health insurance?

- Yes
- No
- Unsure

13. How much of a co-pay or out of pocket expense do you pay for each doctor follow up visit?

- I pay a co-pay of approximately this amount each time: \$_____
- I do NOT pay a co-pay
- I don't know

14. How much money do you spend out of pocket for travel expenses (food, lodging, gas, transportation) to come to each doctor follow-up visit?

\$_____

15. How do you travel to follow-up appointments?

- I provide my own transportation (Travel in your own automobile)
- Ask a friend or family for a ride
- Transportation provided by volunteer
- Bus or public transportation (including Uber or Lyft)
- Other _____
- I prefer not to answer

16. How easy or difficult is it for you to travel to your follow-up appointments?

- Very easy
- Somewhat easy
- Somewhat difficult
- Very difficult

17. How many people live at home with you?

- 0
- 1
- 2-3
- 4 or more
- I prefer not to answer

18. How many financial dependents do you have?

- 0
- 1
- 2-3
- 4 or more
- I prefer not to answer

19. How confident are you filling out forms by yourself?

- All of the time
- Most of the time
- Some of the time
- A little of the time
- None of the time

20. Household Income:

- Less than \$20,000
- \$20,000 to \$34,999
- \$35,000 to \$49,999
- \$50,000 to \$74,999
- \$75,000 to \$99,999
- \$100,000 to \$149,999
- \$150,000 to \$199,999
- \$200,000 or more
- I prefer not to answer

Thank you kindly for participating in this survey!

PUBLICATION FEE FORM

PLEASE READ THIS FORM CAREFULLY. PUBLICATION FEES DO NOT APPLY TO ALL ARTICLE TYPES.

IF YOU HAVE QUESTIONS ABOUT THE PUBLICATION FEE POLICY, PLEASE CONTACT THE EDITORIAL OFFICE AT EditorialOffice@TheOncologist.com.

COMPLETING THIS FORM INDICATES NO PROMISE OF ACCEPTANCE.

PLEASE NOTE: THERE IS **NO** PUBLICATION FEE FOR INVITED PAPERS, LETTERS TO THE EDITOR, OR CLINICAL TRIAL RESULTS SUBMITTED THROUGH THE DEDICATED CTR SUBMISSION SITE.

(Please refer to the [Quick Reference Table](#) on our Information for Authors page for more information.)

Manuscripts that are selected for publication will be charged a publication fee (see the table below for exact amounts). The author agrees to pay this fee to the Publisher within 30 days of receiving the Publisher's invoice.

ARTICLE TYPE	PUBLICATION FEE
Editorial, Commentary, Brief Communications, Precision Medicine Clinic	\$1,500
Review Articles, Original Articles	\$2,500

IF A PUBLICATION FEE CHARGE APPLIES AS DESCRIBED ABOVE, PLEASE COMPLETE THE FIELDS BELOW.

JOURNAL	<i>The Oncologist</i>
ARTICLE TITLE:	
AUTHORS:	
MS NUMBER:	
ARTICLE TYPE:	
PUBLICATION FEE:	
	BILL TO THE ADDRESS BELOW

NOTE: International orders must be paid in currency and drawn on a U.S. bank.

BILL TO:

NAME:	
INSTITUTION:	
MAILING ADDRESS	
PHONE:	
FAX:	
EMAIL:	

NOTE: AT THE TIME OF ACCEPTANCE, AUTHORS MAY ELECT AN OPTIONAL OPEN ACCESS (OA) LICENSE FOR AN ADDITIONAL FEE OF \$1,500. THE PUBLICATION FEE AND THE OPEN ACCESS FEE ARE BILLED SEPARATELY.

Author Manuscript